Lack of change in serum angiotensin-converting enzyme activity during the menstrual cycle

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 4, 2006, Pages 231-235

  Sanders, Julie ^a   Harris, Joanna ^a   Cooper, Jackie ^a   Gohlke, Peter ^b   Humphries, Steve E ^a   Montgomery, Hugh ^c   Woods, David R ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Genotype; Myocardial ischaemia; Oestrogen; Renin angiotensin system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GENE DELETION; GENE INSERTION; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; NORMAL HUMAN; PROGESTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; ESTROGENS; FEMALE; GENOTYPE; HUMANS; MENSTRUAL CYCLE; PEPTIDYL-DIPEPTIDASE A;

EID: 33847706512     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.043     Document Type: Article

References (42)

1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.
2. Witteman JC, Grobbee DE, Kok FJ, Holman A, Valkenburg HA. increased risk of atherosclerosis in women after the menopause. Br Med J 1989;298:642-4.
3. Hamelin BA, Methot J, Arsenault M et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med 2003;114:599-602.
4. Kawano H, Motoyama T, Ohgushi M, Kugiyama K, Ogawa H, Yasue H. Menstrual Cyclic Variation of Myocardial Ischemia in Premenopausal Women with Variant Angina. Ann Intern Med 2001;135:977-81.
5. Hashimoto M, Akishita M, Eto M et al. Modulation of endotheliumdependant flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995;92:3431-5.
6. English JL, Jacobs LO, Green G, Andrews TC. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol 1998;82:256-8.
7. Lloyd GW, Patel NR, McGing E, Cooper AF, Brennand-Roper D, Jackson G. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart 2000;84:189-92.
8. Seltzer A, Pinto JE, Viglione PN et al. Estrogens regulate angiotensin-converting enzyme and angiotensin receptors in female rat anterior pituitary. Neuroendocrinology 1992;55:460-7.
9. Brosnihan KB, Li P, Ganten D, Ferrario CM. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. Am J Physiol 1997;73:R1908-R1915.
10. Dean SA, Tan J, O'brien ER, Leenen FIT. 17(beta)-estradiol downregulates tissue angiotensin converting enzyme and angiotensin II type-1 receptor in female rats. Am J Physiol 2005;288:R759-66.
11. Li J, Hu H-Y, Zhao Y-N. Serum angiotensin-converting enzyme activity in pregnancy-induced hypertension. Gynecol Obstet Invest 1992;33:138-41.
12. Rassmussen AB, Pedersen EB, Romer FK et al. Influence of normotensive pregnancy and pre-eclampsia on angiotensin-converting enzyme. Acta Obstet Gynecol Scand 1983;62:341-4.
13. Sumino H, Ichikawa S, Kanda T et al. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. Am J Hypertens 1999;12:1044-7.
14. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995;8:89-90.
15. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 2001;14:206-11.
16. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004;124:802-08.
17. Nogawa N, Sumino H, Ichikawa S et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001;8:210-15.
18. Miya Y, Sumino H, Ichikawa S et al. Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hypertens Res 2002;25:153-9.
19. Sumino H, Ichikawa S, Ohyama Y et al. Effects of Hormone Replacement Therapy on Serum Angiotensin-Converting Enzyme Activity and Plasma Bradykinin in Postmenopausal Women According to Angiotensin-Converting Enzyme-Genotype. Hypertens Res 2003;26:53-8.
20. Seely EW, Brosnihan KB, Jeunemaitre X, et al. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clinical Endocrinol (Oxf) 2004;60:315-21.
21. Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clinical Endocrinol (Oxf) 2003;58:30-5.
22. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin-1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
23. Danser AHJ, Schalekamp MADH, Bax WA et al. Angiotensin converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995;92: 1387-8.
24. Lindpaintner K, Lee M, Larson MG et al. Absence of association of genetic linkage between the angiotensin converting-enzyme gene and left ventricular mass. N Engl J Med 1996;334:1023-8.
25. Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/ deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000;355:434-42.
26. Cambien F, Poirer O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
27. Schunkert H, Danser AHJ, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:39-45.
28. Staessen JA, Wang JG, Ginocchio G et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15:1579-92.
29. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation 1993;87:V149-55.
30. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta- analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000;342:145-53.
32. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA study). Lancet 2003;362:782-8.
33. O'Dell SD, Humphries SE, Day INM. Rapid methods for population-scale analysis for gene polymorphisms: the ACE gene as an example. Br Heart J 1995;73:368-71.
34. Edling O, Bao G, Feelisch M, Unger T, Gohlke P. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exper Ther 1995;275:854-63.
35. Geisser S, Greenhouse S. An extension of Box's results on the use of the F distribution in multivariate analysis. Ann Math Stat 1958;29:885-91.
36. Shaw KJ, Do YS, Kjos S et al. Human decidua is a major source of renin. J Clin Invest 1989;83:2085-92.
37. Palumbo A, Pourmotabbed G, Carcangiu ML et al. Immuno-localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril 1993;60:280-4.
38. Ahmed A, Li XF, Shams M et al. Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high affinity angiotensin II binding site. J Clin Invest 1995;96:848-57.
39. Svane D, Kahr O, Hansen VB, Holm-Nielsen P, Forman A. Angiotensin-converting enzyme activity and contractile effects of angiotensin I and II in human uteroplacental arteries. Am J Obstet Gynecol 1995;172:991-7.
40. Li XF, Ahmed A. Compartmentalization and cyclic variation of immunoreactivity of renin and angiotensin converting enzyme in human endometrium throughout the menstrual cycle. Hum Reprod 1997;12:2804-09.
41. Saridogan E, Djahanbakhch O, Puddefoot JR et al. Type I angiotensin II receptors in human endometrium. Mol Hum Reprod 1996;2:659-64.
42. Li X-F, Ahmed A. Dual role of angiotensin II in the human endometrium. Hum Reprod 1996;11:101-14.